Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate patients who have achieved virologic suppression (< 400 copies/mL)
on any dual protease inhibitor (PI) combination, to determine whether patients can substitute
both PIs with the single boosted PI darunavir given 600/100 ritonavir (RTV) twice daily (BID)
and maintain comparable virologic suppression (% < 50 c/mL) for 24 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Community Research Initiative of New England
Treatments:
Darunavir HIV Protease Inhibitors Protease Inhibitors Ritonavir